The antiviral drugs market is anticipated to flourish at an average CAGR of 3.9% between 2023 and 2033. The market is expected to hold a market share of US$ 89.68 billion by 2033, while the market is likely to reach a value of US$ 61.42 billion in 2023.
| Attributes | Details |
|---|---|
| Antiviral Drugs Market CAGR (2023 to 2033) | 3.9% |
| Antiviral Drugs Market Size (2023) | US$ 61.42 billion |
| Antiviral Drugs Market Size (2033) | US$ 89.68 billion |
Antiviral drugs are medicines that are used especially for treating viral infections. Most antiviral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum antiviral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen. Instead, they inhibit the development of those viruses.
The global antiviral drugs market is projected to register a moderate growth rate in the pharmaceutical market and is anticipated to increase due to a rise in awareness level, an increase in the diseased population, and the introduction of new drugs with improved efficacy.
Some key patents are reaching their expiry during the forecast periods, such as Combivir, Sustiva, Tenofovir, Tamiflu, Relenza, and Telbivudine. The patent expiries of these blockbuster drugs are expected to trigger generic competition in the antiviral therapeutics market, making the market more competitive.
The late-stage pipeline drugs are expected to enter the market, positively impacting the market. Most antivirals are considered comparatively harmless to the host and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles outside or inside the body. Antiviral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses, and hepatitis B and C viruses.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for antiviral drugs is projected to increase at a CAGR of 3.9% during the forecast period between 2023 and 2033, reaching a total of US$ 89.68 billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.8%.
During the historical outlook, the biggest driver of the overall antiviral drugs market was Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales, which accounted for more than half the share of the market in 2021. According to WHO, in 2021, several patients living with HIV are 38.4 million, and 650k people acquired the disease in the same year.
Nearly four out of five people were freshly put on treatment in sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants. The introduction of solid R&D activities, newer and advanced treatments, and formulations, such as vaccines and combination therapy, are projected to fuel the market growth of antiviral drugs over the forecast period.
The increasing commonness of viral infections such as HIV, Herpes, Influenza, and others is expected to upsurge the demand for antiviral medicines throughout the forecast period. For instance, according to UNAIDS, in 2020, more than 37 billion individuals were living with HIV across the globe. Out of these, around 1.5 billion new people acquired HIV infection in 2020. Overall, the COVID-19 pandemic has pointedly accelerated the market growth in 2021, whereas a negative impact of the pandemic has been detected for other applications of antiviral drugs.
Owing to solid R&D activities, newer and advanced treatments, and formulations, such as vaccines, combination therapy, and others, are being introduced in the market, and the demand is anticipated to upsurge. Hence, strong R&D is one of the crucial factors in the antiviral drugs market growth.
Principal Consultant
Several factors hampering the market expansion of Antiviral Drugs include the high risk of failure, the high cost of R&D and therapy, and government austerity. However, the swelling usage of natural products and the high cost of developing drugs are the market's key challenges.
| Countries | Revenue Share % (2022) |
|---|---|
| United States | 7.1% |
| Germany | 5.8% |
| Japan | 6.4% |
| North America | 38.7% |
| Europe | 24.9% |
| Countries | CAGR % (2023 to 2033) |
|---|---|
| China | 4.7% |
| India | 3.8% |
| United Kingdom | 2.7% |
| Australia | 3.4% |
In terms of market contribution, North America acquired the leading share in revenue collection across the globe, accounting for a 38.7% share in 2022. As per the recent analysis by Future Market Insights, the region is anticipated to maintain its dominance during the assessment period 2022-2032. The United States and Canada are estimated to be the leading shareholders in regional revenue generation.
The market decline can be attributed to the loss of market exclusivity of patented drugs, mounting vaccination rates against viral infections, and government initiatives to minimize the prevalence of viral infections.
For instance, the United States government is responsible for several measures, including funding and grants in infectious diseases programs and encouraging the R&D activities of innovative therapies to manage viral infections.
Based on the geographies, European is the second-leading region, acquiring a 24.9% share in the antiviral drugs market. During the forecast period, the region is estimated to witness moderate growth, backed by soaring investments in the development of new drugs and therapies. This market growth is also attributed to the easy approval and promising healthcare policies by several governments.
In April 2022, European Medicines Agency, the European Union's drug regulator, signed off on emergency usage of Merck's Covid antiviral pill for adults who get tested positive as it prepares to decide on full approval by the year's end.
In July 2021, GSK and Vir announced a Joint Procurement Agreement (JPA) with the European Commission to supply up to 220,000 doses of sotrovimab. Following the grant of the marketing authorization in the EU, Member States participating in the JPA can now order sotrovimab to support their pandemic responses. These initiatives are likely to fuel the market growth of Antiviral Drugs in the coming years.
In the Asia Pacific, the market for antiviral drugs is anticipated to witness the fastest growth rate throughout the forecast period. The market's exponential growth can be attributed to the rising prevalence and treatment rate of viral infections, emerging healthcare infrastructure in the region, and growing awareness among people regarding infectious diseases.
Besides, the strong presence of generic pharmaceutical manufacturing companies in India, China, and other South Asian countries and the rising geriatric population in the region are some principal driving factors of the segment.
The introduction of new and innovative strategies in emerging economies is also likely to boost the demand for Antiviral Drugs over the coming decade.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Category | By Application Type |
|---|---|
| Leading Segment | HIV |
| Market Share (2022) | 44.0% |
| Category | By End Use |
|---|---|
| Leading Segment | Hospitals |
| Market Share (2022) | 47.80% |
The global antiviral drugs market is segmented based on product type and end user. The HIV segment captured the majority share in terms of market revenue generation and held the leading revenue share of 44.0% in 2022.
The segment is projected to observe the fastest growth rate over the forecast period. The rising prevalence of HIV infection associated with a high treatment rate, availability of branded drugs, and government initiatives to upsurge the treatment rate is projected to stimulate the market at a higher growth rate.
For instance, in 2019, the United States government introduced the Ending the HIV Epidemic (EHE) plan to end the HIV epidemic in the country by 2032. The initiative seeks to decrease HIV infections and enhance the diagnosis and treatment rate in the United States. Furthermore, the existence of strong pipeline drugs for HIV infection may also fuel market growth throughout the conjecture period.
The hepatitis segment held the second-leading revenue share in 2021. Escalating vaccination against hepatitis A and B is affecting the growth adversely. Besides, the COVID-19 pandemic has significantly augmented the growth of the other segment in 2020.
Recent Developments:
The market is valued at US$ 61.42 billion in 2023.
AstraZeneca, Cipla, Bayer AG are the key market players.
The growth potential of the market is 3.9% through 2033.
The market is estimated to reach US$ 89.68 billion by 2033.
The market registered a CAGR of 3.8% from 2018 to 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product type, 2023 to 2033
5.3.1. Hepatitis-C antivirals
5.3.2. HIV antivirals
5.3.3. Herpes antivirals
5.3.4. Hepatitis-B antivirals
5.3.5. Influenza antivirals
5.3.6. Others
5.4. Y-o-Y Growth Trend Analysis By Product type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2023 to 2033
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Ambulatory Surgical Centers
6.4. Y-o-Y Growth Trend Analysis By End-user, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End-user, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Product type
8.2.3. By End-user
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Product type
8.3.3. By End-user
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Product type
9.2.3. By End-user
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product type
9.3.3. By End-user
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Product type
10.2.3. By End-user
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product type
10.3.3. By End-user
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Product type
11.2.3. By End-user
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product type
11.3.3. By End-user
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Product type
12.2.3. By End-user
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product type
12.3.3. By End-user
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Product type
13.2.3. By End-user
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product type
13.3.3. By End-user
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Product type
14.2.3. By End-user
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product type
14.3.3. By End-user
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Product type
15.1.2.2. By End-user
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Product type
15.2.2.2. By End-user
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Product type
15.3.2.2. By End-user
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Product type
15.4.2.2. By End-user
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Product type
15.5.2.2. By End-user
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Product type
15.6.2.2. By End-user
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Product type
15.7.2.2. By End-user
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Product type
15.8.2.2. By End-user
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Product type
15.9.2.2. By End-user
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Product type
15.10.2.2. By End-user
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Product type
15.11.2.2. By End-user
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Product type
15.12.2.2. By End-user
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Product type
15.13.2.2. By End-user
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Product type
15.14.2.2. By End-user
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Product type
15.15.2.2. By End-user
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Product type
15.16.2.2. By End-user
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Product type
15.17.2.2. By End-user
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Product type
15.18.2.2. By End-user
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Product type
15.19.2.2. By End-user
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Product type
15.20.2.2. By End-user
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Product type
15.21.2.2. By End-user
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Product type
15.22.2.2. By End-user
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Product type
15.23.2.2. By End-user
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Product type
16.3.3. By End-user
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Roche
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Gilead
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. GlaxoSmithKline
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Bristol-Myers-Squibb
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Abbott
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. AstraZeneca
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Cipla
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Bayer AG
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Johnson & Johnson
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Merck & Co
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. AbbVie
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Aurobindo Pharma
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. Dr. Reddy’s Laboratories Ltd.
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Antiviral Drugs Market
